EGFR and non-small cell lung carcinoma: Given the encouraging results of the AURA trial of osimertinib (administered at 80 or 160 mg daily) as a first-line treatment for patients with EGFR mutation–positive advanced NSCLC, which revealed a median PFS of 20.5 months [31], osimertinib has been evaluated in a randomized phase III trial (FLAURA) in comparison to a standard first-generation EGFR-TKI (gefitinib at 250 mg daily, or erlotinib at 150 mg daily), for treatment-naive patients with EGFR-mutated metastatic NSCLC in the first-line setting.